Results 111 to 120 of about 2,675 (153)
Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7580-7591, August 2026.ABSTRACT Aims To assess whether glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are associated with a lower incidence of age‐related ocular diseases in non‐diabetic older adults with overweight or obesity. Materials and Methods We conducted a retrospective, propensity score–matched cohort study using the TriNetX global research network.
Kuo‐En Chen +3 more
wiley +1 more source
Journal of Diabetes Investigation, Volume 17, Issue 8, Page 1348-1357, August 2026.The dark area of photoreceptor cells, as measured by adaptive optics laser scanning ophthalmoscopy, shows significant enlargement with the progression of diabetic retinopathy (DR). A similar trend is observed for macular vascular leakage assessed by fundus fluorescein angiography. A positive correlation exists between these two parameters, suggesting a
Qi Fang +9 more
wiley +1 more source
Vitreoschisis in Diabetic Macular Edema [PDF]
Investigative Opthalmology & Visual Science, 2011 openaire +2 more sources
Refractory diabetic macular edema.
Journal of ophthalmic & vision research, 2010 openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Disease-a-Month, 2021
Diabetic retinopathy (DR) is a leading cause of preventable blindness world-wide. Diabetic macular edema (DME) is the most common cause of moderate vision loss in patients with diabetes. Although treatments for DME have improved significantly over the past decades, the burden of this disease remains high for patients and the healthcare system alike ...
Melissa, Ixcamey, Camille, Palma
openaire +4 more sources
Diabetic retinopathy (DR) is a leading cause of preventable blindness world-wide. Diabetic macular edema (DME) is the most common cause of moderate vision loss in patients with diabetes. Although treatments for DME have improved significantly over the past decades, the burden of this disease remains high for patients and the healthcare system alike ...
Melissa, Ixcamey, Camille, Palma
openaire +4 more sources
Ophthalmology, 2012
Brasil OFM, 2007, BRIT J OPHTHALMOL, V91, P761, DOI 10.1136-bjo.2006.105783; Gibran SK, 2007, OPHTHALMOLOGY, V114, P890, DOI 10.1016-j.ophtha.2006.11.026; Kim BY, 2006, AM J OPHTHALMOL, V142, P405, DOI 10.1016-j.ajo.2006.04.023; Shin HJ, 2012, GRAEF ARCH CLIN EXP, V250, P61, DOI 10.1007-s00417-011-1774-x; YOUNG RW, 1976, INVEST OPHTH VISUAL, V15 ...
Nicola G, Ghazi +6 more
+7 more sources
Brasil OFM, 2007, BRIT J OPHTHALMOL, V91, P761, DOI 10.1136-bjo.2006.105783; Gibran SK, 2007, OPHTHALMOLOGY, V114, P890, DOI 10.1016-j.ophtha.2006.11.026; Kim BY, 2006, AM J OPHTHALMOL, V142, P405, DOI 10.1016-j.ajo.2006.04.023; Shin HJ, 2012, GRAEF ARCH CLIN EXP, V250, P61, DOI 10.1007-s00417-011-1774-x; YOUNG RW, 1976, INVEST OPHTH VISUAL, V15 ...
Nicola G, Ghazi +6 more
+7 more sources
2010
Diabetic macular edema (DME), defined as a retinal thickening involving or approaching the center of the macula, represents the most common cause of vision loss in patients affected by diabetes mellitus. In the last few years, many diagnostic tools have proven to be useful in the detection and the monitoring of the features characterizing DME.
F. Bandello +6 more
+9 more sources
Diabetic macular edema (DME), defined as a retinal thickening involving or approaching the center of the macula, represents the most common cause of vision loss in patients affected by diabetes mellitus. In the last few years, many diagnostic tools have proven to be useful in the detection and the monitoring of the features characterizing DME.
F. Bandello +6 more
+9 more sources
Current Opinion in Ophthalmology, 2014
Diabetic macular edema (DME) is one of the most common causes of visual loss in patients with diabetes mellitus. Many patients continue to lose vision despite laser photocoagulation and medical therapies. The two major categories of medications currently used to treat DME are corticosteroids and anti-VEGF agents.
Fabio, Patelli +2 more
openaire +4 more sources
Diabetic macular edema (DME) is one of the most common causes of visual loss in patients with diabetes mellitus. Many patients continue to lose vision despite laser photocoagulation and medical therapies. The two major categories of medications currently used to treat DME are corticosteroids and anti-VEGF agents.
Fabio, Patelli +2 more
openaire +4 more sources
International Ophthalmology Clinics, 1976
Photocoagulation by either the argon laser or xenon arc instruments has been reported to have a beneficial effect in selected patients with macular edema. Treatment is not effective in all cases; indeed, in some patients with perifoveal capillary closure, severe macular edema, long-standing organized hard exudates, or significant cystoid maculopathy ...
A, Patz, S L, Fine
openaire +2 more sources
Photocoagulation by either the argon laser or xenon arc instruments has been reported to have a beneficial effect in selected patients with macular edema. Treatment is not effective in all cases; indeed, in some patients with perifoveal capillary closure, severe macular edema, long-standing organized hard exudates, or significant cystoid maculopathy ...
A, Patz, S L, Fine
openaire +2 more sources
Photocoagulation for Diabetic Macular Edema
Archives of Ophthalmology, 1987To the Editor. —In the December 1985 issue of theArchiveswe published data from the Early Treatment Diabetic Retinopathy Study (ETDRS) that demonstrated that focal photocoagulation of "clinically significant" diabetic macular edema substantially reduces the risk of visual loss. 1 As part of the ongoing monitoring of the 23 clinics in this study, we
L M, Aiello, F L, Ferris
openaire +2 more sources